Abstract
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that belongs to the proprotein convertase family. PCSK9 is synthesized as a zymogen and its prodomain is cleaved by its own catalytic activity. The cleaved prodomain forms a protein complex with the rest of the PCSK9 carboxyl terminus within the endoplasmic reticulum and is secreted. Secreted PCSK9 has been shown to be able to reduce low-density lipoprotein receptor (LDLR) levels in vitro and in vivo. Thus PCSK9 has emerged as an important player modulating LDLR levels and plasma LDL cholesterol. Furthermore, PCSK9 deficiency leads to significantly lowered LDL cholesterol levels in humans and provides dramatic protection against coronary heart disease. We review here the current understanding of PCSK9 and its potential as a therapeutic target through which to reduce LDL cholesterol for prevention and treatment of coronary heart disease.
Keywords: PCSK9, LDL cholesterol, LDL receptor, endocytosis, proprotein convertase
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Further LDL Cholesterol Lowering Through Targeting PCSK9 for Coronary Artery Disease
Volume: 8 Issue: 4
Author(s): Guoqing Cao, Yue-Wei Qian, Mark C. Kowala and Robert J. Konrad
Affiliation:
Keywords: PCSK9, LDL cholesterol, LDL receptor, endocytosis, proprotein convertase
Abstract: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that belongs to the proprotein convertase family. PCSK9 is synthesized as a zymogen and its prodomain is cleaved by its own catalytic activity. The cleaved prodomain forms a protein complex with the rest of the PCSK9 carboxyl terminus within the endoplasmic reticulum and is secreted. Secreted PCSK9 has been shown to be able to reduce low-density lipoprotein receptor (LDLR) levels in vitro and in vivo. Thus PCSK9 has emerged as an important player modulating LDLR levels and plasma LDL cholesterol. Furthermore, PCSK9 deficiency leads to significantly lowered LDL cholesterol levels in humans and provides dramatic protection against coronary heart disease. We review here the current understanding of PCSK9 and its potential as a therapeutic target through which to reduce LDL cholesterol for prevention and treatment of coronary heart disease.
Export Options
About this article
Cite this article as:
Cao Guoqing, Qian Yue-Wei, Kowala C. Mark and Konrad J. Robert, Further LDL Cholesterol Lowering Through Targeting PCSK9 for Coronary Artery Disease, Endocrine, Metabolic & Immune Disorders - Drug Targets 2008; 8 (4) . https://dx.doi.org/10.2174/187153008786848286
DOI https://dx.doi.org/10.2174/187153008786848286 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential Options to Treat Hypertriglyceridaemia
Current Drug Targets Erectile Dysfunction and Diabetes Mellitus: Mechanistic Considerations from Studies in Experimental Models
Current Diabetes Reviews Tangier Disease Four Decades of Research: A Reflection of the Importance of HDL
Current Medicinal Chemistry The Frequency of Thrombotic Events Among Adults Given Antifibrinolytic Drugs for Spontaneous Bleeding: Systematic Review and Meta-Analysis of Observational Studies and Randomized Trials
Current Drug Safety Cellular Mechanisms for Diastolic Dysfunction in the Human Heart
Current Pharmaceutical Biotechnology Identify Compounds' Target Against Alzheimer's Disease Based on In-Silico Approach
Current Alzheimer Research Mitochondria-Mediated Oxidative Stress: Old Target for New Drugs
Current Medicinal Chemistry Hypertension and Aortic Stenosis: A Review
Current Hypertension Reviews Obesity and Metabolic Syndrome Affect the Cholinergic Transmission a nd Cognitive Functions
CNS & Neurological Disorders - Drug Targets Evaluating Oxidative Stress in Human Cardiovascular Disease: Methodological Aspects and Considerations
Current Medicinal Chemistry Aliskiren: A New Drug for an Old Problem
Cardiovascular & Hematological Agents in Medicinal Chemistry SDH Genes: From Glomic Tumours to Pheochromocytomas
Current Hypertension Reviews Circadian Cycle and Chronotherapeutics: Recent Trend for the Treatment of Various Biological Disorders
Recent Patents on Drug Delivery & Formulation The Role of Myocardial Collagen Network in Hypertensive Heart Disease
Current Hypertension Reviews Heme Oxygenase-1 against Vascular Insufficiency: Roles of Atherosclerotic Disorders
Current Pharmaceutical Design Statins and Protein Prenylation in Cancer Cell Biology and Therapy
Anti-Cancer Agents in Medicinal Chemistry The Role of An Experimental Model of Atherosclerosis: apoE-knockout Mice in Developing New Drugs against Atherogenesis
Current Pharmaceutical Biotechnology Controversies in Anticoagulant Therapy in Vitreo-Retinal Surgery
Current Pharmaceutical Design Atypical Chemokine Receptors in Inflammatory Disease
Current Molecular Medicine Integrins: Novel Therapeutic Targets for Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry